Tuberculosis test results using fresh versus biobanked urine samples with FujiLAM

• Verfasst von: Broger, Tobias [VerfasserIn]
• Verfasst von: Muyoyeta, Monde [VerfasserIn]
• Verfasst von: Kerkhoff, Andrew D. [VerfasserIn]
• Verfasst von: Denkinger, Claudia M. [VerfasserIn]
• Verfasst von: Moreau, Emmanuel [VerfasserIn]
• Titel: Tuberculosis test results using fresh versus biobanked urine samples with FujiLAM
• Verf.angabe: Tobias Broger, Monde Muyoyeta, Andrew D. Kerkhoff, Claudia M. Denkinger, Emmanuel Moreau
• E-Jahr: 2020
• Jahr: January 01, 2020
• Umfang: 2 S.
• Fussnoten: Gesehen am 17.04.2020
• Titel Quelle: Enthalten in: The lancet <London> / Infectious diseases
• Ort Quelle: New York, NY : Elsevier, 2001
• Jahr Quelle: 2020
• Band/Heft Quelle: 20(2020), 1, Seite 22-23
• ISSN Quelle: 1474-4457
• DOI: doi:10.1016/S1473-3099(19)30684-X
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 169488094X

Abstract

We agree with John T Connelly and colleagues1 that assessment of analyte stability - and matrix effects must be part of every assay validation. It is, however, essential - that validation is done with the assay under consideration, as different lipoarabinomannan - (LAM) assays use different reagents that bind to different LAM epitopes with different - stabilities or availabilities. Therefore, results from the research assay described - by Connelly and colleagues,1 showing rapid signal loss, are not generalisable to other - LAM tests.